Rivus Pharmaceuticals to Present Results from a Phase 2a Tri

Rivus Pharmaceuticals to Present Results from a Phase 2a Trial Evaluating its Controlled Metabolic Accelerator, HU6, at the American Association for the Study of Liver Diseases (AASLD)2022 Meeting

/PRNewswire/ -- Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, today announced the...

Related Keywords

, Shaharyar Khan , Rivus Pharmaceuticals Inc , Rivus Pharmaceuticals , Liver Fat , Top Line Results From , Chief Scientific Officer , Metabolic Trial Design , Controlled Metabolic Accelerator , Nc ,